Loading...

PerCP/Cyanine5.5 anti-human CD4 Antibody

Pricing & Availability
Clone
OKT4 (See other available formats)
Regulatory Status
RUO
Workshop
HCDM listed
Other Names
T4
Isotype
Mouse IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
OKT4_PerCPCyanine55_CD4_Antibody_120518
Human peripheral blood lymphocytes were stained with CD4 (clone OKT4) PerCP/Cyanine5.5 (filled histogram) or Mouse IgG2b, κ PerCP/Cyanine5.5 isotype control (open histogram).
  • OKT4_PerCPCyanine55_CD4_Antibody_120518
    Human peripheral blood lymphocytes were stained with CD4 (clone OKT4) PerCP/Cyanine5.5 (filled histogram) or Mouse IgG2b, κ PerCP/Cyanine5.5 isotype control (open histogram).
See PerCP/Cyanine5.5 spectral data
Cat # Size Price Save
317427 25 tests ¥22,220
317428 100 tests ¥50,380
Description

CD4, also known as T4, is a 55 kD single-chain type I transmembrane glycoprotein expressed on most thymocytes, a subset of T cells, and monocytes/macrophages. CD4, a member of the Ig superfamily, recognizes antigens associated with MHC class II molecules and participates in cell-cell interactions, thymic differentiation, and signal transduction. CD4 acts as a primary receptor for HIV, binding to HIV gp120. CD4 has also been shown to interact with IL-16. 

Product Details
Technical data sheet

Product Details

Reactivity
Human,Cynomolgus,Rhesus
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Human peripheral T cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The OKT4 antibody binds to the D3 domain of CD4 and does not block HIV binding. Additional reported applications (for the relevant formats) include: immunohistochemistry of frozen sections and blocking of T cell activation. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317453 and 317454).

In a small subset of individuals, the OKT4 clone does not bind to CD4 due to polymorphisms in CD4.9

Additional Product Notes
BioLegend is in the process of converting the name PerCP/Cy5.5 to PerCP/Cyanine5.5. The dye molecule remains the same, so you should expect the same quality and performance from our PerCP/Cyanine5.5 products. Contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. 76:4061.
  3. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
  4. Cicin-Sain L, et al. 2010. J. Immunol. 184:6739. PubMed
  5. Rosenzweig M, et al. 2001. J. Med. Primatol. 30:36.
  6. Linder J, et al. 1987. Am. J. Pathol. 127:1.
  7. Boche D, et al. 1999. J. Neurovirol. 5:232. (IHC)
  8. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. USA. 76:4061. (Immunogen)
  9. Lederman S, et al. 1991. Mol Immunol. 28:1171-81.
Product Citations
  1. Shoda H, et al. 2017. Arthritis Research & Therapy . 10.1186/s13075-017-1308-y. PubMed
  2. Chheda ZS, et al. 2018. J Exp Med. 9:19490. PubMed
  3. Neff CP et al. 2018. EBioMedicine. 30:192-202 . PubMed
  4. Su S et al. 2018. Cell. 175(2):442-457 . PubMed
  5. Buchan SL et al. 2018. Immunity. 49(5):958-970 . PubMed
  6. Lopatina T, et al. 2018. Sci Rep. 8:17458. PubMed
  7. Goel G, et al. 2019. Sci Adv. 5:eaaw7756. PubMed
  8. Mann EH, et al. 2019. J Immunol. 202:684. PubMed
  9. Ye C, et al. 2017. J Virol. 91:e01389-23. PubMed
  10. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  11. Charpentier JC, et al. 2020. Nat Commun. 11:180. PubMed
  12. Chiu YL, et al. 2018. Immun Ageing. 15:27. PubMed
  13. Aguilar–Briseñ o JA, et al. 2020. Nat Commun. 2.664583333. PubMed
  14. Zhou R, et al. 2020. Immunity. S1074-7613(20)30333-2.. PubMed
  15. Pham TNQ, et al. 2020. Cell Reports. 29(9):2770-2782.e5.. PubMed
  16. Hu X, et al. 2020. Neoplasia. 1.290972222. PubMed
  17. Shi Y, et al. 2014. Proc Natl Acad Sci U S A. 111:3092.. PubMed
  18. Ferraro A, et al. 2014. Proc Natl Acad Sci U S A. 111:1111. PubMed
  19. Kongsbak M, et al. 2014. PLoS One. 9:96695. PubMed
  20. Jin J, et al. 2014. PLoS One. 9:104753. PubMed
  21. Meira M, et al. 2014. Mult Scler. 20:1363. PubMed
  22. Florek N, et al. 2014. J Virol. 88:13418. PubMed
  23. Crompton J, et al. 2015. Cancer Res. 75:296. PubMed
  24. Ma G, et al. 2015. Proc Natl Acad Sci U S A. 112:2216. PubMed
  25. Ishigaki K, et al. 2015. Sci Rep. 5: 12937. PubMed
  26. Bego M, et al. 2015. J Vis Exp. 103: 51207. PubMed
  27. Heery C, et al. 2015. Cancer Immunol Res. 3: 1248 - 1256. PubMed
  28. Grenga I, et al. 2016. Clin Transl Immunology. 0.265972222. PubMed
  29. Nagafuchi Y, et al. 2016. Sci Rep. 6:29338. PubMed
  30. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  31. Hasaart KAL, et al. 2020. Sci Rep. 10:12991. PubMed
  32. Zavidij O, et al. 2020. Nat Cancer. 0.384027778. PubMed
  33. Alissafi T, et al. 2020. Cell Metabolism. 32(4):591-604.e7. PubMed
  34. Lu C, et al. 2020. Cancer Cell. 39(1):96-108.e6. PubMed
  35. Niu M, et al. 2021. Cell Reports. 36(8):109611. PubMed
  36. Qian Y, et al. 2021. Cell Reports. 36(8):109602. PubMed
  37. Harper JL, et al. 2020. Nat Med. 519:26. PubMed
  38. Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed
  39. Gullà A, et al. 2021. Cancer Discov. 2:468. PubMed
  40. Song TZ, et al. 2021. Front Endocrinol (Lausanne). 12:745984. PubMed
  41. Wu D, et al. 2020. Biomark Res. 8:3. PubMed
  42. Grigoriou M, et al. 2021. Cancer Immunol Res. 9:726. PubMed
  43. Gullà A, et al. 2021. Cancer Discov. . PubMed
  44. Winkler C, et al. 2021. JCI Insight. 6:. PubMed
  45. Imai Y, et al. 2021. JID Innov. 1:100003. PubMed
  46. Costa-Martins AG, et al. 2021. Cell Rep Med. 2:100465. PubMed
  47. Mo Y, et al. 2022. Front Immunol. 12:799896. PubMed
  48. Peng Q, et al. 2022. EBioMedicine. 77:103904. PubMed
  49. Krishnan S, et al. 2021. Clin Exp Immunol. 203:458. PubMed
  50. Weber MG, et al. 2021. JCI Insight. 6:. PubMed
  51. Yamada E, et al. 2021. Gut Microbes. 13:1997292. PubMed
  52. Zhang XL, et al. 2020. J Virol. 94:. PubMed
  53. Wu Y, et al. 2021. Cancer Gene Ther. Online ahead of print. PubMed
  54. Wang N, et al. 2021. iScience. 24:103205. PubMed
  55. Sun Y, et al. 2022. Nat Commun. 13:3916. PubMed
  56. Chan JA, et al. 2022. Nat Commun. 13:4159. PubMed
  57. Weymar GHJ, et al. 2022. Cell Rep. 40:111311. PubMed
  58. Newton HS, et al. 2021. Mol Ther Methods Clin Dev. 21:133. PubMed
  59. Liu H, et al. 2021. Virology. 560:76. PubMed
  60. Grivas A, et al. 2022. Front Immunol. 13:964274. PubMed
  61. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
  62. Ellis GI, et al. 2022. Cell Rep Med. 3:100614. PubMed
  63. Graciliano NG, et al. 2023. Front Immunol. 13:1031248. PubMed
  64. Edwards CL, et al. 2023. J Clin Invest. 133: . PubMed
  65. Cai Z, et al. 2023. Adv Sci (Weinh). 10:e2207155. PubMed
  66. Xie Q, et al. 2023. iScience. 26:106395. PubMed
  67. Pfister F, et al. 2023. Methods Mol Biol. 2644:331. PubMed
  68. Patskovsky Y, et al. 2023. Nat Commun. 14:3763. PubMed
RRID
AB_1186124 (BioLegend Cat. No. 317427)
AB_1186122 (BioLegend Cat. No. 317428)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, 55 kD
Distribution

T cell subset, majority of thymocytes, monocytes/macrophages

Function
MHC class II co-receptor, lymphocyte adhesion, thymic differentiation, HIV receptor
Ligand/Receptor
MHC class II molecules, HIV gp120, IL-16
Cell Type
Macrophages, Monocytes, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Center D, et al. 1996. Immunol. Today 17:476.
2. Gaubin M, et al. 1996. Eur. J. Clin. Chem. Clin. Biochem. 34:723.

Gene ID
920 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?

PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.

Go To Top Version: 5    Revision Date: 12/05/2018

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account